471-480 of 575 results for 'consumer data right'

FIRB changes to note from 1 July 2023
Insight 29 Jun 2023

In this Insight, we outline and comment on the New Register and corresponding reporting obligations. ...

ASIC's New Document Production Guidelines
Insight 11 Mar 2020

ASIC has released its new Document Production Guidelines, which govern how it expects electronic and hard copy records to be produced in response to compulsory notices. ...

Changes to open and transparent sale process requirement for foreign persons acquiring agricultural land
Insight 22 Oct 2018

On 25 September 2018 the Foreign Investment Review Board released revised guidance on the application of the requirement for an open and transparent sale process for foreign persons acquiring agricultural land Partner Wendy Rae Senior Associate Julian Barendse and Lawyer Bianca Sacco examine these ...

Regulatory scrutiny of private capital increases
Insight 28 Feb 2025

Private capital is becoming a growing focus of regulators, both in Australia and internationally, given the ever-increasing flow of capital to the sector in recent years. ...

Interlocutory injunction refused based on 'doubtful' patent term extension
Insight 23 Feb 2022

In the fight against patent infringement, challenging the validity of patent term extensions (PTEs) is increasingly becoming the weapon of choice for generic pharmaceutical companies. Since around the mid-2000s, patentees in pharmaceutical patent cases have typically been successful in bids for interlocutory injunctions, aiming to prevent the launch of generic products in Australia. The recent Biogen decision by the Federal Court is the latest in a trend of refusing interlocutory injunctions, and a clear indication the tide is turning. ...

Patent term extensions under siege: a new era of challenges for pharmaceutical patentees
Insight 24 Nov 2024

A recent Federal Court decision has struck down a patent term extension granted to Novartis for its blockbuster heart failure drug Entresto. The decision in Novartis AG v Pharmacor Pty Limited follows a recent trend of successful challenges by generic pharmaceutical companies. ...

New ASIC guidance on how superannuation and managed funds can avoid 'greenwashing'
Insight 16 Jun 2022

Greenwashing in the promotion of managed investment and superannuation funds is one of ASIC's current corporate governance priorities as it continues to 'monitor the market … looking for misleading claims about ESG and sustainability'. ...

Nucleus – corporate law developments: major FIRB law changes; ASIC extends relief for financial reporting and AGM requirements; and other corporate law developments
Insight 08 Feb 2021

Major foreign investment law changes; ASIC extends relief for financial reporting and AGM requirements and issues guidance on design and distribution laws; ASX issues guidance to address 'earning surprises'; ACCC releases first digital platform inquiry interim report; and WA Supreme Court hands down decision with implications for legal professional privilege in internal emails. ...

Major proposed changes to FIRB regime
Insight 05 Jun 2020

On 5 June 2020 the Federal Treasurer announced major proposed changes to Australia's FIRB regime to address national security risks and ensure greater compliance with FIRB approval conditions. ...

The ASX Listing Rules up for review but still fit for purpose: the case for retaining the existing policy settings on reverse takeovers
Insight 13 Oct 2025

Merger transactions without a vote of the shareholders of each merger party are back in the headlines as a second deal sparks fresh tension and mounting calls from the Australian investment community ...

Refine